U.S. Markets closed

Exelixis, Inc. (EXEL)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
20.17+0.37 (+1.87%)
At close: 4:00PM EDT

20.74 0.57 (2.83%)
After hours: 7:01PM EDT

People also watch
  • What are the chances the PPS will be over $50 by the end of the year?
  • BIG MONEY IS ACCUMULATED BIG TIME. Something is up. Probably last chance ever to buy here...
  • Pretty solid volume. Reassuring
  • Asco is the event that puts focus on oncology stocks, it tends to float all boats. What we need to remember is the submission cut off date for Abstracts was back on Feb 2, most data in the presentation was more than six months ago. What we want to see is updates that excite, last years proclamation that " Exel set the Gold Standard in RCC" was one such benefit of the conference to Exel.
  • ASCO to watch List
    JUNE 4
    Abstract 4562
    A phase I study of cabozantinib plus nivolumab (CaboNivo) and
    cabonivo plus ipilimumab (CaboNivoIpi) in patients (pts) with
    refractory metastatic (m) urothelial carcinoma (UC) and other
    genitourinary (GU) tumors.
    Poster Board: #240
    Andrea B. Apolo, M.D. - First Author
    Genitourinary Malignancies Branch, Center for Cancer Research,
    National Cancer Institute, National Institutes of Health
  • •04:52 am (EXEL, URBN, CHS +2) Watch These 5 Huge Put Purchases In Wednesday Trade
    I don't know much about option trading. Can someone explain how do PUT and CALL options may affect to the stock price value?
  • Social, are we still looking at Cabo ph 3 interim results for HCC by end of June? I ask because BMY just got priority reviews for Opdivo for HCC in Previously Treated HCC....
    U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb's Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma

    11:15 am ET May 24, 2017 (BusinessWire) Print
    Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) that seeks to extend the use of Opdivo (nivolumab) to patients with hepatocellular carcinoma (HCC) after prior sorafenib therapy. The FDA granted the application priority review and previously granted Opdivo orphan-drug designation for the treatment of HCC. The FDA action date is September 24, 2017.

    "We believe the FDA acceptance of our application for Opdivo with priority review status is an important recognition of the significant unmet need for patients with HCC, which is often diagnosed in the advanced stage when treatment options are limited," said Ian M. Waxman, M.D., development lead, Gastrointestinal Cancers, Bristol-Myers Squibb. "We are committed to exploring new treatment options for these patients and look forward to working with the FDA to potentially extend the use of Opdivo as a treatment option in this setting."

    The submission was based on data from the Phase 1/2 CheckMate -040 study investigating Opdivo in advanced HCC patients with and without hepatitis B virus or hepatitis C virus infections. Data from this study were recently published in The Lancet and will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017 during a poster discussion session on June 3, 2017 from 4:45-6:00 PM CDT in Hall D2.

    About Hepatocellular Carcinoma

    Hepatocellular carcinoma (HCC) is the most common type of liver cancer and the second most frequent cause of cancer death worldwide. More than 700,000 people around the world, including about 40,000 people in the United States, are diagnosed with HCC each year. The majority of these cases are caused by hepatitis B virus (HBV) or hepatitis C virus (HCV) infections, making HBV/HCV the most common risk factors for liver cancer.

    HCC is often diagnosed in the advanced stage where treatment options are limited and outcomes are poor, with one-year survival rates in the advanced setting of approximately 44%. For patients who are intolerant to or who have progressed during sorafenib therapy, median survival remains less than 11 months with currently available treatment options.

    Bristol-Myers Squibb & Immuno-Oncology: Advancing Oncology Research

    At Bristol-Myers Squibb, patients are at the center of everything we do. Our vision for the future of cancer care is focused on researching and developing transformational Immuno-Oncology (I-O) medicines for hard-to-treat cancers that could potentially improve outcomes for these patients.

    We are leading the scientific understanding of I-O through our extensive portfolio of investigational compounds and approved agents. Our differentiated clinical development program is studying broad patient populations across more than 35 types of cancers with 14 clinical-stage molecules designed to target different immune system pathways. Our deep expertise and innovative clinical trial designs position us to advance I-O/I-O, I-O/chemotherapy, I-O/targeted therapies and I-O/radiation therapies across multiple tumors and potentially deliver the next wave of therapies with a sense of urgency. We also continue to pioneer research that will help facilitate a deeper understanding of the role of immune biomarkers and how patients' individual tumor biology can be used as a guide for treatment decisions throughout their journey.

    We understand making the promise of I-O a reality for the many patients who may benefit from these therapies requires not only innovation on our part but also close collaboration with leading experts in the field. Our partnerships with academia, government, advocacy and biotech companies support our collective goal of providing new treatment options to advance the standards of clinical practice.

    About Opdivo

    Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore anti-tumor immune response. By harnessing the body's own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

    Opdivo's leading global development program is based on Bristol-Myers Squibb's scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

    In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 60 countries, including the United States, the European Union and Japan. In October 2015, the company's Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.
  • Very little volume today, at least the selling has abated.
  • Just a crazy observation from an old trader - if last week's whippy action continues, I consider it an extremely bullish signal. Just watch it bounce from the 19's.
  • Hello hello ! So, we just made some lunch money for the rest of the week. How are you feeling ? all those who cried on this board last Monday and were willing to sell. Shame on those who sold. You boys will never learn.
  • Finally.... the reborn of EXEL
  • Big fund this fund was selling is still not done yet...but seems like end is there. Dont worry another big fund will jump in at these bargain prices. Perhaps this fund was waiting to see if a buyout would happen but I am fine with weak funds leaving the party. There is a lot more to come and we haven't even heard about HCC results and the renal 1st line filing. Today may be the turning point and we should head higher. I would hope that the climb up is slow and steady
  • We are oversold, no question.
  • As soon as you see appearance of yahoo MB trolls like Walter ...you know the bottom is in. This is a good sign that we have bottomed. Regardless, yes its painful to watch 25% drop without cause, but rest assured there has been no bad news at all. If anything the last quarterly report was a block-buster. Remember back in September the PPS went up to $15, and then without any reason it fell all the way down to $10.88 - a drop of 27%. Here we went pretty close to $25 and down to $19 - a drop of about 24%. The last time it recovered all of the loss and then some. It wont be any different this time. Loo at the analyst targets - $24 to $28 with average at $26.20. We are at 19 and change. We have %25 move in not so distant future.
  • Biotech swings can be erratic. White knuckle. The fear I sense on this board suggests we may be oversold. Solid company. Approved drug. Good balance sheet. Just relax.
  • when the trolls appear, the end to the selling is near!
  • Contemplated selling, but I will hang in there. I agree with comments that there looks to be someone large getting out, but that is not the problem. The problem is no one is here buying. The price dropped 50 cents on 200k volume this morning.

    RSI is the lowest is has been. Stochastic indicates oversold. MACD is at a low...on and on. Eventually the market is going to wake up and buying pressure should take it up as quick as it came down...probably quicker...

    I admit I came in early on this one though...oh well, tough to call the tops and the bottoms as a retail...
  • I guess my point is that I'm not abandoning this stock. Just waiting.
  • It looks like the big seller{s}, is running out of shares. Let's see if the volume slows as the price rebounds. The new owners of those shares will be happy folks in a short time.
  • Hopefully they will announce a news tomorrow morning.